Pharmaceutical tablet
Latest Pfizer Inc. Patents:
- Pyrrolo[2,3-d]pyrimidinyl, Pyrrolo[2,3-b]pyrazinyl and Pyrrolo[2,3-d]pyridinyl Acryla-mides
- METHODS AND DOSING REGIMENS COMPRISING A CDK2 INHIBITOR FOR THE TREATMENT OF CANCER
- MELANOCORTIN 4 RECEPTOR ANTAGONISTS AND USES THEREOF
- Solid Forms of 2-[(4-{6-[(4-Cyano-2-fluorobenzyl)oxy]pyridin-2-yl}piperidin-1-yl)methyl]-1-[(2S)-oxetan-2-ylmethyl]-1H-benzimidazole-6-carboxylic acid, 1,3-Dihydroxy-2-(hydroxymethyl)propan-2-amine Salt
- Pyrido[4,3-d]pyrimidine compounds
Description
FIG. 1 is a front elevational view of a pharmaceutical tablet of my new design;
FIG. 2 is a top plan view thereof;
FIG. 3 is a bottom plan view thereof;
FIG. 4 is a side elevation view thereof; and
FIG. 5 is a back elevation view of the pharmaceutical tablet shown in FIGS. 1-4.
Referenced Cited
U.S. Patent Documents
D144978 | June 1946 | Owen |
D190729 | June 1961 | Carter |
D229175 | November 1973 | Libertone et al. |
Patent History
Patent number: D263172
Type: Grant
Filed: Sep 18, 1979
Date of Patent: Feb 23, 1982
Assignee: Pfizer Inc. (New York, NY)
Inventor: Kenneth J. Payne (Greenwich, CT)
Primary Examiner: Veronica O'Keefe
Law Firm: Connolly and Hutz
Application Number: 6/76,589
Type: Grant
Filed: Sep 18, 1979
Date of Patent: Feb 23, 1982
Assignee: Pfizer Inc. (New York, NY)
Inventor: Kenneth J. Payne (Greenwich, CT)
Primary Examiner: Veronica O'Keefe
Law Firm: Connolly and Hutz
Application Number: 6/76,589
Classifications
Current U.S. Class:
D28/2;
D28/1;
D 1/12;
Individual Panel Mount Type (13) (D18/29);
424/14;
424/15
International Classification: D2801;
International Classification: D2801;